Combinations of ezetimibe with nonstatin drug regimens affecting lipid metabolism

Expert Review of Cardiovascular Therapy

Volumn 9, Issue 3, 2011, Pages 355-366

  Agouridis, Aris P ^a   Filippatos, Theodosios D ^a   Tsimihodimos, Vasilios ^a   Elisaf, Moses S ^a  

^a UNIVERSITY OF IOANNINA   (Greece)

Author keywords

cholestyramine; colesevelam; colestipol; ezetimibe; fenofibrate; n 3 fatty acids; nicotinic acid; orlistat; pioglitazone; plant stanols; plant sterols; rosiglitazone

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ACARBOSE; ATORVASTATIN; COLESEVELAM; COLESTIPOL; COLESTYRAMINE; EZETIMIBE; FENOFIBRATE; FENOFIBRIC ACID; GLITAZONE DERIVATIVE; METFORMIN; NICOTINIC ACID; OMEGA 3 FATTY ACID; PHYTOSTEROL; PIOGLITAZONE; PLACEBO; RIMONABANT; SIBUTRAMINE; SIMVASTATIN; TETRAHYDROLIPSTATIN;

ABSENCE OF SIDE EFFECTS; DIABETES MELLITUS; FLUSHING; GASTROINTESTINAL DISEASE; HUMAN; HYPERLIPIDEMIA; LIPID METABOLISM; MENTAL DISEASE; OBESITY; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SIDE EFFECT;

AZETIDINES; DRUG THERAPY, COMBINATION; HUMANS; HYPERLIPIDEMIAS; HYPOLIPIDEMIC AGENTS; LIPID METABOLISM;

EID: 79953251805     PISSN: 14779072     EISSN: 17448344     Source Type: Journal    
DOI: 10.1586/erc.11.4     Document Type: Review

References (79)

1. Filippatos TD, Mikhailidis DP. Lipidlowering drugs acting at the level of the gastrointestinal tract. Curr. Pharm. Des. 15(5), 490-516 (2009). Comprehensive review of the mechanism of action, role and efficacy of drugs acting at the gastrointestinal level.
2. Altmann SW, Davis HR Jr, Zhu LJ et al. Niemann-Pick C1 like 1 protein is critical for intestinal cholesterol absorption. Science 303(5661), 1201-1204 (2004). (Pubitemid 38233587)
3. Garcia-Calvo M, Lisnock J, Bull HG et al. The target of ezetimibe is Niemann-Pick C1-like 1 (NPC1L1). Proc. Natl Acad. Sci. USA 102(23), 8132-8137 (2005). (Pubitemid 40800055)
4. Meng CQ. Ezetimibe (Schering-Plough). Curr. Opin. Investig. Drugs 2(3), 389-392 (2001).
5. Sweeney ME, Johnson RR. Ezetimibe: An update on the mechanism of action, pharmacokinetics and recent clinical trials. Expert Opin. Drug Metab. Toxicol. 3(3), 441-450 (2007). (Pubitemid 47316034)
6. Kalogirou M, Tsimihodimos V, Elisaf M. Pleiotropic effects of ezetimibe: Do they really exist? Eur. J. Pharmacol. 633(1-3), 62-70 (2010).
7. Baigent C, Keech A, Kearney PM et al. Efficacy and safety of cholesterol-lowering treatment: Prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 366(9493), 1267-1278 (2005).
8. Kiortsis DN, Filippatos TD, Mikhailidis DP, Elisaf MS, Liberopoulos EN. Statin-associated adverse effects beyond muscle and liver toxicity. Atherosclerosis 195(1), 7-16 (2007). (Pubitemid 47561937)
9. Einarsson K, Ericsson S, Ewerth S et al. Bile acid sequestrants: Mechanisms of action on bile acid and cholesterol metabolism. Eur. J. Clin. Pharmacol. 40(Suppl. 1), S53-S58 (1991).
10. Grundy SM, Ahrens EH Jr, Salen G. Interruption of the enterohepatic circulation of bile acids in man: Comparative effects of cholestyramine and ileal exclusion on cholesterol metabolism. J. Lab. Clin. Med. 78(1), 94-121 (1971).
11. Shepherd J, Packard CJ, Bicker S, Lawrie TD, Morgan HG. Cholestyramine promotes receptor-mediated low-densitylipoprotein catabolism. N. Engl. J. Med. 302(22), 1219-1222 (1980). (Pubitemid 10112393)
12. Bays H, Rhyne J, Abby S, Lai YL, Jones M. Lipid-lowering effects of colesevelam HCl in combination with ezetimibe. Curr. Med. Res. Opin. 22(11), 2191-2200 (2006). (Pubitemid 44789984)
13. Zema MJ. Colesevelam HCl and ezetimibe combination therapy provides effective lipid-lowering in difficult-to-treat patients with hypercholesterolemia. Am. J. Ther. 12(4), 306-310 (2005). A study of the role of ezetimibe/ colesevelam combination in difficult-totreat patients with hypercholesterolemia. (Pubitemid 41391808)
14. Xydakis AM, Guyton JR, Chiou P, Stein JL, Jones PH, Ballantyne CM. Effectiveness and tolerability of ezetimibe add-on therapy to a bile acid resin-based regimen for hypercholesterolemia. Am. J. Cardiol. 94(6), 795-797 (2004). (Pubitemid 39221507)
15. Rivers SM, Kane MP, Busch RS, Bakst G, Hamilton RA. Colesevelam hydrochloride-ezetimibe combination lipid-lowering therapy in patients with diabetes or metabolic syndrome and a history of statin intolerance. Endocr. Pract. 13(1), 11-16 (2007).
16. Knopp RH, Tsunehara C, Retzlaff BM et al. Lipoprotein effects of combined ezetimibe and colesevelam hydrochloride versus ezetimibe alone in hypercholesterolemic subjects: A pilot study. Metabolism 55(12), 1697-1703 (2006). (Pubitemid 44830137)
17. Filippatos T, Milionis HJ. Treatment of hyperlipidaemia with fenofibrate and related fibrates. Expert Opin. Investig Drugs 17(10), 1599-1614 (2008).
18. Milionis HJ, Elisaf MS, Mikhailidis DP. Treatment of dyslipidaemias in patients with established vascular disease: A revival of the fibrates. Curr. Med. Res. Opin. 16(1), 21-32 (2000). (Pubitemid 30107749)
19. Elisaf M. Effects of fibrates on serum metabolic parameters. Curr. Med. Res. Opin. 18(5), 269-276 (2002). (Pubitemid 35014543)
20. Tsimihodimos V, Miltiadous G, Daskalopoulou SS, Mikhailidis DP, Elisaf MS. Fenofibrate: Metabolic and pleiotropic effects. Curr. Vasc. Pharmacol. 3(1), 87-98 (2005). (Pubitemid 40089531)
21. Keech A, Simes RJ, Barter P et al. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with Type 2 diabetes mellitus (the FIELD study): Randomised controlled trial. Lancet 366(9500), 1849-1861 (2005).
22. Tziomalos K, Athyros VG. Fenofibrate: A novel formulation (triglide) in the treatment of lipid disorders: A review. Int. J. Nanomedicine 1(2), 129-147 (2006).
23. Bairaktari ET, Tzallas CS, Tsimihodimos VK, Liberopoulos EN, Miltiadous GA, Elisaf MS. Comparison of the efficacy of atorvastatin and micronized fenofibrate in the treatment of mixed hyperlipidemia. J. Cardiovasc. Risk 6(2), 113-116 (1999). (Pubitemid 29298071)
24. Farnier M, Bonnefous F, Debbas N, Irvine A. Comparative efficacy and safety of micronized fenofibrate and simvastatin in patients with primary type IIa or IIb hyperlipidemia. Arch. Intern. Med. 154(4), 441-449 (1994). (Pubitemid 24072218)
25. Agouridis AP, Filippatos TD, Derdemezis CS, Mikhailidis DP, Elisaf MS. Combination of fenofibrate with non-statin drug regimens. Curr. Pharm. Des. 16(30), 3401-3416 (2010).
26. Farnier M, Freeman MW, Macdonell G et al. Efficacy and safety of the coadministration of ezetimibe with fenofibrate in patients with mixed hyperlipidaemia. Eur. Heart J. 26(9), 897-905 (2005). (Pubitemid 40676570)
27. Mckenney JM, Farnier M, Lo KW et al. Safety and efficacy of long-term coadministration of fenofibrate and ezetimibe in patients with mixed hyperlipidemia. J. Am. Coll. Cardiol. 47(8), 1584-1587 (2006). A study investigating the long-term efficacy and safety of ezetimibe/ fenofibrate combination treatment.
28. Bays HE, Shah A, Macdonell G, Taggart WV, Gumbiner B. Effects of coadministered ezetimibe plus fenofibrate in mixed dyslipidemic patients with metabolic syndrome. Metab. Syndr. Relat. Disord. DOI: 10.1089/met.2010.0068 (2010) (Epub ahead of print).
29. Kumar S, Lahey KA, Day A, Lahaye SA. Comparison of the efficacy of administering a combination of ezetimibe plus fenofibrate versus atorvastatin monotherapy in the treatment of dyslipidemia. Lipids Health Dis. 8(17), 56 (2009).
30. Ansquer JC, Bekaert I, Guy M, Hanefeld M, Simon A. Efficacy and safety of coadministration of fenofibrate and ezetimibe compared with each as monotherapy in patients with type IIb dyslipidemia and features of the metabolic syndrome: A prospective, randomized, double-blind, three-parallel arm, multicenter, comparative study. Am. J. Cardiovasc. Drugs 9(2), 91-101 (2009). Interesting study that investigated the effects of ezetimibe/fenofibrate combination in patients with the metabolic syndrome.
31. Gazi IF, Tsimihodimos V, Tselepis AD, Elisaf M, Mikhailidis DP. Clinical importance and therapeutic modulation of small dense low-density lipoprotein particles. Expert Opin. Biol. Ther. 7(1), 53-72 (2007). (Pubitemid 46091576)
32. Gazi I, Tsimihodimos V, Filippatos T, Bairaktari E, Tselepis AD, Elisaf M. Concentration and relative distribution of low-density lipoprotein subfractions in patients with metabolic syndrome defined according to the National Cholesterol Education Program criteria. Metabolism 55(7), 885-891 (2006). (Pubitemid 43902890)
33. Filippatos TD, Tsimihodimos V, Kostapanos M et al. Small dense LDL cholesterol and apolipoproteins C-II and C-III in non-diabetic obese subjects with metabolic syndrome. Arch. Med. Sci. 4(3), 263-269 (2008).
34. Tribble DL, Farnier M, Macdonell G et al. Effects of fenofibrate and ezetimibe, both as monotherapy and in coadministration, on cholesterol mass within lipoprotein subfractions and low-density lipoprotein peak particle size in patients with mixed hyperlipidemia. Metabolism 57(6), 796-801 (2008). (Pubitemid 351697911)
35. Kosoglou T, Statkevich P, Fruchart JC et al. Pharmacodynamic and pharmacokinetic interaction between fenofibrate and ezetimibe. Curr. Med. Res. Opin. 20(8), 1197-1207 (2004). (Pubitemid 39120784)
36. Chan DC, Chen MM, Ooi EM, Watts GF. An ABC of apolipoprotein C-III: A clinically useful new cardiovascular risk factor? Int. J. Clin. Pract. 62(5), 799-809 (2008). (Pubitemid 351533666)
37. Kosoglou T, Statkevich P, Johnson-Levonas AO, Paolini JF, Bergman AJ, Alton KB. Ezetimibe: A review of its metabolism, pharmacokinetics and drug interactions. Clin. Pharmacokinet. 44(5), 467-494 (2005). (Pubitemid 40733733)
38. Gustavson LE, Schweitzer SM, Burt DA et al. Evaluation of the potential for pharmacokinetic interaction between fenofibrate and ezetimibe: A Phase I, open-label, multiple-dose, three-period crossover study in healthy subjects. Clin. Ther. 28(3), 373-387 (2006). (Pubitemid 43783438)
39. Farnier M, Roth E, Gil-Extremera B et al. Efficacy and safety of the coadministration of ezetimibe/simvastatin with fenofibrate in patients with mixed hyperlipidemia. Am. Heart J. 153(2), 335. e1-e8 (2007).
40. Gil-Extremera B, Mendez G, Zakson M et al. Efficacy and safety of ezetimibe/ simvastatin coadministered with fenofibrate in mixed hyperlipidemic patients with metabolic syndrome. Metab. Syndr. Relat. Disord. 5(4), 305-314 (2007). (Pubitemid 350208898)
41. Farnier M, Perevozskaya I, Taggart WV, Kush D, Mitchel YB. VAP II analysis of lipoprotein subclasses in mixed hyperlipidemic patients on treatment with ezetimibe/simvastatin and fenofibrate. J. Lipid Res. 49(12), 2641-2647 (2008).
42. Moutzouri E, Kei A, Elisaf MS, Milionis HJ. Management of dyslipidemias with fibrates, alone and in combination with statins: Role of delayed-release fenofibric acid. Vasc. Health Risk Manag. 6, 525-539 (2010).
43. Jones PH, Goldberg AC, Knapp HR et al. Efficacy and safety of fenofibric acid in combination with atorvastatin and ezetimibe in patients with mixed dyslipidemia. Am. Heart J. 160(4), 759-766 (2010).
44. Sanyal S, Kuvin JT, Karas RH. Niacin and laropiprant. Drugs Today 46(6), 371-378 (2010).
45. Perry CM. Extended-release niacin (nicotinic acid)/laropiprant. Drugs 69(12), 1665-1679 (2009).
46. Jelesoff NE, Ballantyne CM, Xydakis AM, Chiou P, Jones PH, Guyton JR. Effectiveness and tolerability of adding ezetimibe to niacin-based regimens for treatment of primary hyperlipidemia. Endocr. Pract. 12(2), 159-164 (2006).
47. Guyton JR, Brown BG, Fazio S, Polis A, Tomassini JE, Tershakovec AM. Lipidaltering efficacy and safety of ezetimibe/ simvastatin coadministered with extendedrelease niacin in patients with type IIa or type IIb hyperlipidemia. J. Am. Coll. Cardiol. 51(16), 1564-1572 (2008). (Pubitemid 351509420)
48. Fazio S, Guyton JR, Polis AB et al. Long-term safety and efficacy of triple combination ezetimibe/simvastatin plus extended-release niacin in patients with hyperlipidemia. Am. J. Cardiol. 105(4), 487-494 (2010).
49. Fazio S, Guyton JR, Lin J, Tomassini JE, Shah A, Tershakovec AM. Long-term efficacy and safety of ezetimibe/ simvastatin coadministered with extendedrelease niacin in hyperlipidaemic patients with diabetes or metabolic syndrome. Diabetes Obes. Metab. 12(11), 983-993 (2010).
50. Kosoglou T, Zhu Y, Statkevich P et al. Assessment of potential pharmacokinetic interactions of ezetimibe/simvastatin and extended-release niacin tablets in healthy subjects. Eur. J. Clin. Pharmacol. 2, 120-34 (2010).
51. Derdemezis CS, Filippatos TD, Mikhailidis DP, Elisaf MS. Review article: Effects of plant sterols and stanols beyond low-density lipoprotein cholesterol lowering. J. Cardiovasc. Pharmacol. Ther. 15(2), 120-134 (2010).
52. Jakulj L, Trip MD, Sudhop T, Von Bergmann K, Kastelein JJ, Vissers MN. Inhibition of cholesterol absorption by the combination of dietary plant sterols and ezetimibe: Effects on plasma lipid levels. J. Lipid Res. 46(12), 2692-2698 (2005). Interesting study describing the effects of the combination of ezetimibe and plant sterol - drugs that act at the level of the GI tract. (Pubitemid 43107481)
53. Filippatos T, Derdemezis C, Elisaf M. Effects of orlistat, alone or combined with hypolipidemic drugs, on cardiovascular risk factors. J. Clin. Lipidol. 4(3), 331-341 (2009).
54. Filippatos TD, Derdemezis CS, Gazi IF, Nakou ES, Mikhailidis DP, Elisaf MS. Orlistat-associated adverse effects and drug interactions: A critical review. Drug Saf. 31(1), 53-65 (2008).
55. Kiortsis DN, Filippatos TD, Elisaf MS. The effects of orlistat on metabolic parameters and other cardiovascular risk factors. Diabetes Metab. 31(1), 15-22 (2005). (Pubitemid 40327588)
56. Kiortsis DN, Tsouli S, Filippatos TD, Konitsiotis S, Elisaf MS. Effects of sibutramine and orlistat on mood in obese and overweight subjects: A randomised study. Nutr. Metab. Cardiovasc. Dis. 18(3), 207-210 (2008). (Pubitemid 351374797)
57. Filippatos TD, Kiortsis DN, Liberopoulos EN, Georgoula M, Mikhailidis DP, Elisaf MS. Effect of orlistat, micronised fenofibrate and their combination on metabolic parameters in overweight and obese patients with the metabolic syndrome: The FenOrli study. Curr. Med. Res. Opin. 21(12), 1997-2006 (2005). (Pubitemid 41803111)
58. Filippatos TD, Gazi IF, Liberopoulos EN et al. The effect of orlistat and fenofibrate, alone or in combination, on small dense LDL and lipoprotein-associated phospholipase A2 in obese patients with metabolic syndrome. Atherosclerosis 193(2), 428-437 (2007). (Pubitemid 47058108)
59. Filippatos TD, Derdemezis CS, Georgoula M, Kiortsis DN, Tselepis AD, Elisaf MS. Fenofibrate and orlistat, alone or in combination, do not alter plasma visfatin levels in subjects with metabolic syndrome. J. Med. Sci. Res. 2, 9-10 (2007).
60. Filippatos TD, Liberopoulos EN, Kostapanos M et al. The effects of orlistat and fenofibrate, alone or in combination, on high-density lipoprotein subfractions and pre-b1-HDL levels in obese patients with metabolic syndrome. Diabetes Obes. Metab. 10(6), 476-483 (2008). (Pubitemid 351639090)
61. Filippatos T, Tsimihodimos V, Kostapanos M et al. Analysis of the 6-month effect of orlistat, alone or in combination with fenofibrate, administration on triglyceriderich lipoprotein metabolism in overweight and obese patients with metabolic syndrome. J. Clin. Lipidol. 2(4), 279-284 (2008).
62. Nakou ES, Filippatos TD, Georgoula M et al. The effect of orlistat and ezetimibe, alone or in combination, on serum LDL and small dense LDL cholesterol levels in overweight and obese patients with hypercholesterolaemia. Curr. Med. Res. Opin. 24(7), 1919-1929 (2008). Interesting study describing the effects of the combination of ezetimibe and orlistat, drugs that act at the level of the GI tract.
63. Tellis CC, Tselepis AD. The role of lipoprotein-associated phospholipase A2 in atherosclerosis may depend on its lipoprotein carrier in plasma. Biochim. Biophys. Acta 1791(5), 327-338 (2009).
64. Tsimikas S, Tsironis LD, Tselepis AD. New insights into the role of lipoprotein(a)-associated lipoproteinassociated phospholipase A2 in atherosclerosis and cardiovascular disease. Arterioscler. Thromb. Vasc. Biol. 27(10), 2094-2099 (2007). (Pubitemid 350287235)
65. Gazi I, Lourida ES, Filippatos T, Tsimihodimos V, Elisaf M, Tselepis AD. Lipoprotein-associated phospholipase A2 activity is a marker of small, dense LDL particles in human plasma. Clin. Chem. 51(12), 2264-2273 (2005). (Pubitemid 41692569)
66. Tzotzas T, Filippatos TD, Triantos A, Bruckert E, Tselepis AD, Kiortsis DN. Effects of a low-calorie diet associated with weight loss on lipoprotein-associated phospholipase A2 (Lp-PLA2) activity in healthy obese women. Nutr. Metab. Cardiovasc. Dis. 18(7), 477-482 (2008).
67. Nakou ES, Filippatos TD, Kiortsis DN et al. The effects of ezetimibe and orlistat, alone or in combination, on high-density lipoprotein (HDL) subclasses and HDL-associated enzyme activities in overweight and obese patients with hyperlipidaemia. Expert Opin. Pharmacother. 9(18), 3151-3158 (2008).
68. Mackness MI, Mackness B, Durrington PN. Paraoxonase and coronary heart disease. Atheroscler. Suppl. 3(4), 49-55 (2002). (Pubitemid 38234486)
69. Tsimihodimos V, Karabina SA, Tambaki AP et al. Atorvastatin preferentially reduces LDL-associated platelet-activating factor acetylhydrolase activity in dyslipidemias of type IIA and type IIB. Arterioscler. Thromb. Vasc. Biol. 22(2), 306-311 (2002). (Pubitemid 34127044)
70. Mackness MI, Arrol S, Abbott C, Durrington PN. Protection of low-density lipoprotein against oxidative modification by high-density lipoprotein associated paraoxonase. Atherosclerosis 104(1-2), 129-135 (1993). (Pubitemid 24035640)
71. Mackness MI, Mackness B, Durrington PN, Connelly PW, Hegele RA. Paraoxonase: Biochemistry, genetics and relationship to plasma lipoproteins. Curr. Opin. Lipidol. 7(2), 69-76 (1996). (Pubitemid 26167018)
72. Nakou ES, Filippatos TD, Agouridis AP, Kostara C, Bairaktari ET, Elisaf MS. The effects of ezetimibe and/or orlistat on triglyceride-rich lipoprotein metabolism in obese hypercholesterolemic patients. Lipids 45(5), 445-450 (2010).
73. Florentin M, Kostapanos MS, Nakou ES, Elisaf M, Liberopoulos EN. Efficacy and safety of ezetimibe plus orlistat or rimonabant in statin-intolerant nondiabetic overweight/obese patients with dyslipidemia. J. Cardiovasc. Pharmacol. Ther. 14(4), 274-282 (2009).
74. Bianchi C, Miccoli R, Daniele G, Penno G, Del Prato S. Is there evidence that oral hypoglycemic agents reduce cardiovascular morbidity/mortality? Yes. Diabetes Care 32(Suppl. 2), S342-S348 (2009).
75. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with Type 2 diabetes (UKPDS 34). Lancet 352(9131), 854-865 (1998).
76. Rizos CV, Liberopoulos EN, Mikhailidis DP, Elisaf MS. Pleiotropic effects of thiazolidinediones. Expert Opin. Pharmacother. 9(7), 1087-1108 (2008). (Pubitemid 351721748)
77. Gaudiani LM, Lewin A, Meneghini L et al. Efficacy and safety of ezetimibe coadministered with simvastatin in thiazolidinedione-treated Type 2 diabetic patients. Diabetes Obes. Metab. 7(1), 88-97 (2005).
78. Yamagishi S, Matsui T, Ueda S, Fukami K, Okuda S. Clinical utility of acarbose, an a-glucosidase inhibitor in cardiometabolic disorders. Curr. Drug Metab. 10(2), 159-163 (2009).
79. Nozaki Y, Fujita K, Yoneda M et al. Long-term combination therapy of ezetimibe and acarbose for non-alcoholic fatty liver disease. J. Hepatol. 51(3), 548-556 (2009).